Prestige Consumer Healthcare Inc. — FY2024 Form 10-K
Reporting period: Fiscal year ended March 31, 2024; filed May 15, 2024. The request metadata says “2023 Q4,” but this filing is the annual report for fiscal 2024 and includes fourth-quarter results. Unless stated otherwise, dollar amounts below are in U.S. dollars.
Business context
Prestige develops, markets, sells and distributes branded over-the-counter health and personal care products. It reports North American and International OTC Healthcare segments. North America represented 85.2% of FY2024 revenue and International 14.8%. Major brands include Monistat, Dramamine, Summer’s Eve, Fleet, Clear Eyes and TheraTears.
Financial performance and liquidity
| Metric | FY2024 | FY2023 |
|---|---|---|
| Total revenue | $1,125.4 million | $1,127.7 million |
| Gross profit / gross margin | $624.4 million / 55.5% | $625.3 million / 55.4% |
| Operating income (loss) | $342.4 million | $(22.4) million |
| Net income (loss) | $209.3 million | $(82.3) million |
| Diluted EPS | $4.17 | $(1.65) |
| Cash from operating activities | $248.9 million | $229.7 million |
- Revenue was nearly flat year over year: North American revenue fell 1.6% to $958.3 million, while International revenue rose 8.5% to $167.1 million.
- North American women’s health, cough and cold, and analgesics declined; international women’s health, eye and ear care, and analgesics grew. Eye and ear product shortages adversely affected fourth-quarter results.
- Gross margin edged up to 55.5%, with product mix and pricing actions partly offset by higher supply-chain costs. Segment contribution margin, the company’s measure of segment profitability, declined to 41.9% from 42.6%, principally reflecting higher advertising and marketing expense.
- FY2024 net income compares with a FY2023 loss that included $370.2 million of goodwill and tradename impairment charges. No impairment charge was recorded in FY2024.
- Cash from operations increased by $19.2 million, attributed to lower working capital needs and higher net income before non-cash items. Capital expenditures were $9.6 million; operating cash flow less capital expenditures was approximately $239.4 million.
- Cash was $46.5 million at year-end. Current assets were $375.0 million and current liabilities $117.0 million. Total debt principal was $1.135 billion ($1.126 billion net of unamortized debt costs), versus $1.360 billion principal a year earlier. The company repaid $225 million of term loans during FY2024.
- The company had no ABL revolver borrowings and reported $171 million of available borrowing capacity. It was in compliance with debt covenants at year-end and said it expects to remain compliant in FY2025. Interest expense was $67.2 million; average borrowing cost rose to 5.4% from 4.8%.
Material changes, outlook and risks
- FY2024 sales were pressured by supplier capacity constraints and product shortages, particularly in eye care. Management expects further shortages may weigh on sales. The company also cited labor availability, raw-material and freight costs, inflation, interest rates, and geopolitical uncertainty as potential pressures.
- The company relies substantially on outside manufacturers: 122 third-party manufacturers, with one supplier accounting for approximately 20% of gross revenue. It provided that supplier short-term loans totaling $5.9 million at March 31, 2024.
- Customer concentration is material. Walmart represented 19.7% and Amazon 10.9% of FY2024 gross revenue. The company generally has no long-term customer purchase agreements.
- Goodwill and intangible assets totaled $2.848 billion, a large share of total assets. FY2024 impairment testing found no impairment, but a 50-basis-point increase in the discount rate would have triggered an estimated $9.1 million goodwill impairment for North American Women’s Health and $3.2 million of impairment across indefinite-lived intangibles.
- Management said cash generated from operations and existing credit facilities should be adequate for working capital and capital expenditures over the next 12 months, excluding acquisitions; this is not quantified earnings guidance. The filing provides no formal revenue or EPS forecast.
- On May 6, 2024, the Board authorized up to $300 million of additional share repurchases. FY2024 repurchases under the program were $25 million. The company does not expect to pay common-stock dividends in the foreseeable future.
- Other key risks include regulation and product recalls, competition and private-label products, customer and supplier concentration, debt covenants and variable interest rates, foreign exchange, cybersecurity, litigation, and potential future impairment charges. Routine legal matters were not expected to be material, taking reserves into account.
- PwC issued unqualified audit opinions on the financial statements and internal control over financial reporting. The audit identified impairment valuation of selected indefinite-lived tradenames and North American Women’s Health goodwill as critical audit matters.
Important facts for investors to verify
- Whether eye-care and other supplier shortages have eased, and the extent of any ongoing lost sales or customer backorders.
- Whether pricing and cost savings can offset input-cost inflation without damaging demand or market share.
- Debt repayment capacity, variable-rate exposure, covenant headroom and the refinancing or repayment plan for the 2028 maturities.
- Assumptions supporting the carrying values of Summer’s Eve, TheraTears and North American Women’s Health goodwill, given the disclosed impairment sensitivities.
- The credit quality and repayment prospects of the $5.9 million supplier loan, as well as continued supply from the concentrated manufacturer.
- How the $300 million repurchase authorization will be funded and balanced against debt reduction, acquisitions and operating needs.